Akari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical Progress
Akari Therapeutics Plc - American Depositary Shares (AKTX)
US:NASDAQ Investor Relations:
investor.akaritx.com/investor-relations
Company Research
Source: GlobeNewswire
- Positive early safety and efficacy data with nomacopan Phase II clinical study in patients with mild-to-moderate bullous pemphigoid (BP) announced April 2019Phase I/II clinical study in patients with moderate-to-severe atopic keraconjunctivitis (AKC) announced June 2019Further clinical data from BP and AKC trials anticipated Q4 2019 - Pivotal clinical trial for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) expected to start Q4 2019 FDA Fast Track designation granted August 2019 - Long term treatment data continues to accumulate Approximately 20 cumulative patient-years of data with no drug related serious adverse eventsPositive data reported across paroxysmal nocturnal haemoglobinuria (PNH), BP and thrombotic microangiopathy (TMA) patients on chronic and acute systemic nomacopan treatment NEW YORK and LONDON, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a
Show less
Read more
Impact Snapshot
Event Time:
AKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKTX alerts
High impacting Akari Therapeutics Plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AKTX
News
- Akari Therapeutics, Plc (NASDAQ: AKTX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Akari Therapeutics, Plc (NASDAQ: AKTX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Akari Therapeutics Announces Key Leadership AppointmentsGlobeNewswire
- Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial OfficerGlobeNewswire
- Akari Therapeutics, Plc (NASDAQ: AKTX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat